Pandemic Pushes India's Pharma Industry Growth To 59%

COVID-19 pandemic has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector.

On the MAT (moving annual turnover) basis, IPM grew 9.6 per cent, primarily driven by pricing growth of 4.3 per cent and new product launch growth of 4.6 per cent. Volume growth was muted at 0.8 per cent.

Existing Pharmaceutical Agent Treats Aggressive Brain Cancer
Surfen can be used to treat GBM. The research team used cultured cells to observe binding properties of the this drug compound.

‘According to total sales audit data from world's largest pharmaceutical market research firm IMS Health, the Indian Pharma Market (IPM) grew 59 per cent yoy in April, 2021 vs 16 per cent yoy in March, 2021 due to the low base effect in April, 2020 and sharp surge in Covid-19-related sales.’

Tweet it Now

According to a report from Emkay Global Financial Services, all major therapies posted high double-digit growth in April 21.

Within Chronic therapies, Cardiac therapy grew 22 per cent. Similarly Anti-diabetic therapy grew 10 per cent. VMS (vitamins, minerals and supplements) posted record growth of 80 per cent in April 21 vs 27 per cent in March 21.

The growth in respiratory therapy rebounded sharply at 64 per cent in April 21 after falling for nine consecutive months.

Relaunch of New Index That Tracks Impact of Pharmaceuticals Worldwide
Index that tracks the impact of pharmaceuticals worldwide more accurately and to focus on more diseases will be relaunched.

As per the brokerage, DRL grew the fastest at 79 per cent yoy followed by Cipla (77 per cent yoy) and Cadila (53 per cent yoy). Sun Pharma, Lupin and Ipca Labs reported growth of 30-52 per cent yoy.

Other notable outperformers are Glenmark (172 per cent), Aristo (77 per cent), Macleods (69 per cent), and Alkem (82 per cent).

Millions of New Cyclic Compounds with Pharmaceutical Value Identified
A new method developed helps generate a large number of unique cyclic compounds, and some of can interrupt protein-protein interactions, which play a significant role in the disease.

While IPM growth could be strong in the next couple of months, driven by surging Covid-19-related sales and likely impact of stocking up, we believe growth could normalize as Covid-19 would delay normalization, Emkay said.

Source-IANS

AIMIL Pharmaceuticals Set to Launch Ayurvedic Medicines in Europe
AIMIL Pharmaceuticals, which has already made a mark in South Asian markets, Kuwait, Sri Lanka and Nepal, has technical collaboration in Canada and Commonwealth countries.